Elicio Therapeutics, Inc., a clinical-stage biotechnology company, has announced its financial results for the first quarter ending March 31, 2025. The company reported a net loss of $11.2 million, which is a decrease from the $11.8 million loss recorded in the first quarter of 2024. Operating expenses increased to $10.7 million compared to $10.2 million in the previous year, driven by higher research and development costs. However, the loss per share improved to $0.87 from $1.15 in the same period last year. As of March 31, 2025, Elicio's cash and cash equivalents were $18.4 million, with expectations to sustain operations into the fourth quarter of 2025, extending beyond the anticipated Phase 2 interim analysis of the AMPLIFY-7P clinical trial. The company also reported a $0.5 million non-cash other expense from a change in the fair value of the warrant liability. Elicio has made significant strides in its corporate strategy, including the appointment of Preetam Shah as Chief Strategy and Financial Officer in March 2025 and securing a $10 million registered direct offering of common stock and warrants in January 2025. Elicio has also aligned with the FDA on the Phase 3 study design of ELI-002, focusing on a registrational strategy in post-resection mKRAS PDAC. The interim analysis for the Phase 2 AMPLIFY-7P trial, focused on disease-free survival, is expected in the third quarter of 2025.